China Rush Over? Korean Firms Step Up To Seize Opportunities
Strong BIO Presence Signals Intent
Executive Summary
Falling foreign investment and increasing business uncertainties in China could present new opportunities for the Korean biopharma sector, which is stepping up globalization and R&D efforts to seek growth.
You may also be interested in...
Hard Decoupling: Foreign Firms Less Optimistic About China But Health Sector Revenues Growing
Latest US trade group business survey shows R&D-based pharma and medical device companies continue to see China as an important growth driver but amid unequal market access, ongoing regulatory concerns, and patchy IP protection improvements.
Could ASEAN Become Next Priority For Korean Pharma Firms?
Southeast Asia has so far not been a priority market for South Korean pharma firms, largely because of challenges such as access and affordability for patients. But a Deloitte executive suggested at a recent seminar that technology-based medicines, for example using next-generation formulation technologies, could be an initial focus for Korean firms looking to enter the rapidly growing ASEAN grouping.
Korean Biotech Roundup: String Of Positive R&D Developments Outweighs Some Setbacks
The South Korean biotech space has been marked by multiple positive R&D developments and pipeline and partnering progress in recent months, more than outweighing some other setbacks for the rapidly developing sector.